688073 毕得医药
已收盘 02-09 15:00:01
资讯
新帖
简况
2月9日毕得医药发生2笔大宗交易 成交金额475.2万元
证券之星 · 02-09 17:32
2月9日毕得医药发生2笔大宗交易 成交金额475.2万元
每周股票复盘：毕得医药（688073）现多笔折价大宗交易
证券之星 · 02-08 02:28
每周股票复盘：毕得医药（688073）现多笔折价大宗交易
股市必读：2月5日毕得医药现400.74万元大宗交易
证券之星 · 02-06
股市必读：2月5日毕得医药现400.74万元大宗交易
股市必读：2月2日毕得医药现1笔折价17.64%的大宗交易 合计成交206.88万元
证券之星 · 02-03
股市必读：2月2日毕得医药现1笔折价17.64%的大宗交易 合计成交206.88万元
每周股票复盘：毕得医药（688073）审议修订董高薪酬制度
证券之星 · 02-01
每周股票复盘：毕得医药（688073）审议修订董高薪酬制度
毕得医药拟修订董高薪酬制度，强化激励约束机制
中金财经 · 01-31
毕得医药拟修订董高薪酬制度，强化激励约束机制
毕得医药（688073）披露2026年第一次临时股东会会议资料，1月30日股价下跌9.04%
证券之星 · 01-30
毕得医药（688073）披露2026年第一次临时股东会会议资料，1月30日股价下跌9.04%
1月30日毕得医药跌9.04%，信澳健康中国混合A基金重仓该股
证券之星 · 01-30
1月30日毕得医药跌9.04%，信澳健康中国混合A基金重仓该股
每周股票复盘：毕得医药（688073）戴岚减持计划完成持股降至32.48%
证券之星 · 01-25
每周股票复盘：毕得医药（688073）戴岚减持计划完成持股降至32.48%
上海毕得医药董事会提名委员会工作细则出炉，规范董事及高管选任
中金财经 · 01-24
上海毕得医药董事会提名委员会工作细则出炉，规范董事及高管选任
毕得医药（688073）披露股东减持计划完成暨减持股份结果公告，1月23日股价上涨2.02%
证券之星 · 01-23
毕得医药（688073）披露股东减持计划完成暨减持股份结果公告，1月23日股价上涨2.02%
毕得医药：1月21日至1月22日高管戴岚减持股份合计3.43万股
证券之星 · 01-22
毕得医药：1月21日至1月22日高管戴岚减持股份合计3.43万股
每周股票复盘：毕得医药（688073）高管戴岚两日合计减持8万股
证券之星 · 01-18
每周股票复盘：毕得医药（688073）高管戴岚两日合计减持8万股
毕得医药：1月13日高管戴岚减持股份合计3万股
证券之星 · 01-13
毕得医药：1月13日高管戴岚减持股份合计3万股
1月13日毕得医药涨5.28%，兴业医疗保健混合A基金重仓该股
证券之星 · 01-13
1月13日毕得医药涨5.28%，兴业医疗保健混合A基金重仓该股
毕得医药：1月12日高管戴岚减持股份合计5万股
证券之星 · 01-12
毕得医药：1月12日高管戴岚减持股份合计5万股
每周股票复盘：毕得医药（688073）股东拟合计减持近10%股份
证券之星 · 01-11
每周股票复盘：毕得医药（688073）股东拟合计减持近10%股份
毕得医药（688073）披露股东减持股份计划公告，1月7日股价上涨1.47%
证券之星 · 01-07
毕得医药（688073）披露股东减持股份计划公告，1月7日股价上涨1.47%
毕得医药(688073.SH)股东拟合计减持不超3%股份
智通财经 · 01-06
毕得医药(688073.SH)股东拟合计减持不超3%股份
毕得医药股东拟减持不超过总股本3%股份，减持期1月28日至4月27日
美股速递 · 01-06
毕得医药股东拟减持不超过总股本3%股份，减持期1月28日至4月27日
加载更多
公司概况
公司名称：
上海毕得医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2022-10-11
主营业务：
上海毕得医药科技股份有限公司的主营业务是为新药研发机构提供专业、高效的药物分子砌块及科学试剂产品及服务。公司的主要产品是分子砌块杂环化合物、分子砌块苯环化合物、分子砌块脂肪族类化合物、催化剂和配体、活性小分子化合物。
发行价格：
88.00
{"stockData":{"symbol":"688073","market":"SH","secType":"STK","nameCN":"毕得医药","latestPrice":61.36,"timestamp":1770620401000,"preClose":61.55,"halted":0,"volume":925640,"delay":0,"changeRate":-0.0031,"floatShares":43234200,"shares":90882900,"eps":1.6869,"marketStatus":"已收盘","change":-0.19,"latestTime":"02-09 15:00:01","open":61.52,"high":62.69,"low":60.82,"amount":57332200,"amplitude":0.0304,"askPrice":61.36,"askSize":1,"bidPrice":61.33,"bidSize":8,"shortable":0,"etf":0,"ttmEps":1.6869,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770687000000},"marketStatusCode":5,"adr":0,"adjPreClose":61.55,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770600600000,1770607800000],[1770613200000,1770620400000]],"highLimit":67.71,"lowLimit":55.39,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":90882948,"isCdr":false,"pbRate":2.78,"roa":"--","peRate":36.374415,"roe":"5.93%","epsLYR":1.32,"committee":0.136364,"marketValue":5577000000,"turnoverRate":0.0214,"status":1,"afterMarket":{"amount":10299766.88,"volume":167858,"close":61.36,"buyVolume":800,"sellVolume":0,"time":1770622437558,"indexStatus":"已收盘 02-09 15:30:00","preClose":61.55},"floatMarketCap":2653000000},"requestUrl":"/m/hq/s/688073","defaultTab":"news","newsList":[{"id":"2610635380","title":"2月9日毕得医药发生2笔大宗交易 成交金额475.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610635380","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610635380?lang=zh_cn&edition=full","pubTime":"2026-02-09 17:32","pubTimestamp":1770629560,"startTime":"0","endTime":"0","summary":"证券之星消息，2月9日毕得医药发生大宗交易，交易数据如下：近三个月该股共发生22笔大宗交易，合计成交1.44万手，折价成交22笔。该股近期无解禁股上市。截至2026年2月9日收盘，毕得医药(688073)报收于61.36元，下跌0.31%，换手率2.14%，成交量9256.0手，成交额5733.22万元。该股近半年内有股东持股变动，合计净减持102.24万股，股东增减持明细如下表：该股最近90天内共有2家机构给出评级，买入评级2家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900022482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2609152686","title":"每周股票复盘：毕得医药（688073）现多笔折价大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2609152686","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609152686?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:28","pubTimestamp":1770488892,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，毕得医药报收于61.55元，较上周的59.86元上涨2.82%。本周，毕得医药2月4日盘中最高价报63.8元。2月2日盘中最低价报58.28元。毕得医药当前最新总市值55.94亿元，在医疗服务板块市值排名32/51，在两市A股市值排名3216/5186。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2609588443","title":"股市必读：2月5日毕得医药现400.74万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2609588443","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609588443?lang=zh_cn&edition=full","pubTime":"2026-02-06 01:38","pubTimestamp":1770313089,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，毕得医药报收于61.58元，下跌1.94%，换手率2.17%，成交量9364.0手，成交额5833.2万元。来自交易信息汇总：同日发生400.74万元大宗交易，显示存在一定规模的机构或大户间交易行为。交易信息汇总资金流向2月5日主力资金净流出857.9万元，占总成交额14.71%；游资资金净流入907.87万元，占总成交额15.56%；散户资金净流出49.97万元，占总成交额0.86%。大宗交易2月5日毕得医药现400.74万元大宗交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600001426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2608941458","title":"股市必读：2月2日毕得医药现1笔折价17.64%的大宗交易 合计成交206.88万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608941458","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608941458?lang=zh_cn&edition=full","pubTime":"2026-02-03 02:57","pubTimestamp":1770058629,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，毕得医药报收于58.28元，下跌2.64%，换手率3.88%，成交量1.68万手，成交额9927.66万元。当日关注点来自交易信息汇总：2月2日毕得医药获主力资金净流入64.21万元，游资资金净流入480.73万元。大宗交易2月2日毕得医药现1笔折价17.64%的大宗交易，合计成交206.88万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300001747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2608077771","title":"每周股票复盘：毕得医药（688073）审议修订董高薪酬制度","url":"https://stock-news.laohu8.com/highlight/detail?id=2608077771","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608077771?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:30","pubTimestamp":1769887833,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，毕得医药报收于59.86元，较上周的70.6元下跌15.21%。本周，毕得医药1月26日盘中最高价报72.2元。本周关注点公司公告汇总：审议《关于修订<董事、高级管理人员薪酬管理制度>的议案》公司公告汇总毕得医药：2026年第一次临时股东会会议资料上海毕得医药科技股份有限公司将于2026年2月9日召开2026年第一次临时股东会，审议《关于修订<董事、高级管理人员薪酬管理制度>的议案》。本次股东会由董事会召集，董事长戴岚主持。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2607073042","title":"毕得医药拟修订董高薪酬制度，强化激励约束机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2607073042","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607073042?lang=zh_cn&edition=full","pubTime":"2026-01-31 11:31","pubTimestamp":1769830266,"startTime":"0","endTime":"0","summary":"中访网数据 上海毕得医药科技股份有限公司于2026年1月24日发布公告，拟召开2026年第一次临时股东会，审议修订《董事、高级管理人员薪酬管理制度》的议案。该议案旨在规范公司董事及高级管理人员的薪酬管理，建立科学有效的激励与约束机制，以调动其积极性。议案已由公司第二届董事会第三十次会议审议通过。根据公告，本次临时股东会将于2026年2月9日上午9:30在上海市杨浦区公司会议室以现场结合网络投票的方式举行，网络投票通过上海证券交易所系统进行。会议将审议上述单一议案。此次制度修订是公司完善治理结构、优化高管激励体系的重要举措，预计将对公司长期人才稳定与战略执行产生积极影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260131/31989176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2607538042","title":"毕得医药（688073）披露2026年第一次临时股东会会议资料，1月30日股价下跌9.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607538042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607538042?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:16","pubTimestamp":1769786175,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，毕得医药报收于59.86元，较前一交易日下跌9.04%，最新总市值为54.4亿元。该股当日开盘65.68元，最高66.57元，最低58.03元，成交额达2.27亿元，换手率为8.64%。近日，毕得医药发布2026年第一次临时股东会会议资料公告。公告显示，公司将于2026年2月9日召开2026年第一次临时股东会，审议《关于修订<董事、高级管理人员薪酬管理制度>的议案》。本次股东会由董事会召集，董事长戴岚主持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2607846090","title":"1月30日毕得医药跌9.04%，信澳健康中国混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2607846090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607846090?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:35","pubTimestamp":1769762132,"startTime":"0","endTime":"0","summary":"证券之星消息，1月30日毕得医药跌9.04%创60日新低，收盘报59.86元，换手率8.64%，成交量3.73万手，成交额2.27亿元。重仓毕得医药的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为信达澳亚基金的信澳健康中国混合A。信澳健康中国混合A目前规模为4.09亿元，最新净值2.416，较上一交易日下跌1.02%，近一年上涨16.52%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000027847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2606320762","title":"每周股票复盘：毕得医药（688073）戴岚减持计划完成持股降至32.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606320762","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606320762?lang=zh_cn&edition=full","pubTime":"2026-01-25 03:23","pubTimestamp":1769282590,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，毕得医药报收于70.6元，较上周的70.31元上涨0.41%。本周关注点股本股东变化：戴岚减持148,835股，减持计划已实施完毕，持股比例降至32.48%。股本股东变化高管增减持2026年1月21日至1月22日，公司董事、高级管理人员戴岚减持3.43万股，占总股本0.0377%。股东减持计划完成暨减持股份结果公告本次减持计划实施前，戴岚持有公司32.64%股份。因自身资金需要，其计划通过集中竞价减持不超过148,835股。减持后戴岚持股比例降至32.48%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500001195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2605284674","title":"上海毕得医药董事会提名委员会工作细则出炉，规范董事及高管选任","url":"https://stock-news.laohu8.com/highlight/detail?id=2605284674","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605284674?lang=zh_cn&edition=full","pubTime":"2026-01-24 09:19","pubTimestamp":1769217580,"startTime":"0","endTime":"0","summary":"中访网数据 上海毕得医药科技股份有限公司近日公布了其董事会提名委员会工作细则，旨在规范公司董事及高级管理人员的遴选与任命程序，进一步完善公司治理结构。根据细则，提名委员会由三名董事组成，其中独立董事占多数，并由独立董事担任主任委员。该细则自董事会决议通过之日起施行，其制定与实施有助于提升上海毕得医药公司治理的规范性与透明度，强化董事会决策的专业性与独立性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260124/31968984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2605409186","title":"毕得医药（688073）披露股东减持计划完成暨减持股份结果公告，1月23日股价上涨2.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605409186","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605409186?lang=zh_cn&edition=full","pubTime":"2026-01-23 23:09","pubTimestamp":1769180956,"startTime":"0","endTime":"0","summary":"近日，毕得医药披露《股东减持计划完成暨减持股份结果公告》。公告显示，本次减持计划实施前，戴岚持有毕得医药32.64%股份。因自身资金需要，戴岚计划通过集中竞价交易方式减持不超过148,835股，即不超过公司总股本的0.16%。截至2026年1月22日，戴岚已累计减持148,835股，减持价格区间为65.10至75.00元/股，减持总金额为10,344,897.74元，本次减持计划已实施完毕。减持后戴岚持股比例降至32.48%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2605495551","title":"毕得医药：1月21日至1月22日高管戴岚减持股份合计3.43万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495551","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605495551?lang=zh_cn&edition=full","pubTime":"2026-01-22 20:01","pubTimestamp":1769083295,"startTime":"0","endTime":"0","summary":"证券之星消息，根据1月22日市场公开信息、上市公司公告及交易所披露数据整理，毕得医药最新董监高及相关人员股份变动情况：2026年1月21日至2026年1月22日公司董事,高级管理人员戴岚共减持公司股份3.43万股，占公司总股本为0.0377%。变动期间公司股价上涨3.92%，1月22日当日收盘报69.2元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200036411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2604496923","title":"每周股票复盘：毕得医药（688073）高管戴岚两日合计减持8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2604496923","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604496923?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:02","pubTimestamp":1768676531,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，毕得医药报收于70.31元，较上周的69.35元上涨1.38%。本周关注点股本股东变化：董事戴岚1月12日减持5万股，占总股本0.055% 股本股东变化：董事戴岚1月13日减持3万股，占总股本0.033% 股本股东变化高管增减持2026年1月13日，公司董事、高级管理人员戴岚减持3.0万股，占公司总股本0.033%。当日股价上涨5.28%，收盘报72.93元。2026年1月12日，公司董事、高级管理人员戴岚减持5.0万股，占公司总股本0.055%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2603110686","title":"毕得医药：1月13日高管戴岚减持股份合计3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603110686","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603110686?lang=zh_cn&edition=full","pubTime":"2026-01-13 20:02","pubTimestamp":1768305756,"startTime":"0","endTime":"0","summary":"证券之星消息，根据1月13日市场公开信息、上市公司公告及交易所披露数据整理，毕得医药最新董监高及相关人员股份变动情况：2026年1月13日公司董事,高级管理人员戴岚共减持公司股份3.0万股，占公司总股本为0.033%。变动期间公司股价上涨5.28%，1月13日当日收盘报72.93元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300037734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2603488505","title":"1月13日毕得医药涨5.28%，兴业医疗保健混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603488505","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603488505?lang=zh_cn&edition=full","pubTime":"2026-01-13 15:35","pubTimestamp":1768289740,"startTime":"0","endTime":"0","summary":"证券之星消息，1月13日毕得医药涨5.28%，收盘报72.93元，换手率5.65%，成交量2.44万手，成交额1.81亿元。重仓毕得医药的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共9家，其中持有数量最多的公募基金为兴业基金的兴业医疗保健混合A。兴业医疗保健混合A目前规模为2.61亿元，最新净值0.8825，较上一交易日上涨0.02%，近一年上涨41.45%。该公募基金现任基金经理为陈旭。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300020422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2602142865","title":"毕得医药：1月12日高管戴岚减持股份合计5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602142865","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602142865?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:02","pubTimestamp":1768219353,"startTime":"0","endTime":"0","summary":"证券之星消息，根据1月12日市场公开信息、上市公司公告及交易所披露数据整理，毕得医药最新董监高及相关人员股份变动情况：2026年1月12日公司董事,高级管理人员戴岚共减持公司股份5.0万股，占公司总股本为0.055%。变动期间公司股价下跌0.12%，1月12日当日收盘报69.27元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200032619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2602365735","title":"每周股票复盘：毕得医药（688073）股东拟合计减持近10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2602365735","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602365735?lang=zh_cn&edition=full","pubTime":"2026-01-11 03:52","pubTimestamp":1768074755,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，毕得医药报收于69.35元，较上周的61.05元上涨13.6%。本周关注点公司公告汇总：补充确认2025年度日常关联交易合计金额554.91万元及24.00万美元。股本股东变化：欣曦管理、兰旦管理及吴波拟合计减持不超过2,726,488股。公司公告汇总：更正2025年半年度报告，补充披露与西格莱的关联交易及应收应付余额。股本股东变化截至2026年1月7日，股东欣曦管理持有公司5.19%股份，兰旦管理持有3.94%股份，吴波持有0.86%股份，三方为一致行动人，合计持股10.00%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2601851879","title":"毕得医药（688073）披露股东减持股份计划公告，1月7日股价上涨1.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601851879","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601851879?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:36","pubTimestamp":1767778597,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，毕得医药报收于67.58元，较前一交易日上涨1.47%，最新总市值为61.42亿元。近日，毕得医药发布股东减持股份计划公告。截至公告披露日，公司股东欣曦管理持有公司5.19%股份，兰旦管理持有3.94%股份，吴波持有0.86%股份，三方为一致行动人，合计持股10.00%。本次减持期间为2026年1月28日至4月27日，减持价格将按市场价格确定。公司表示，本次减持计划未违反此前已作出的承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700027337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2601895734","title":"毕得医药(688073.SH)股东拟合计减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2601895734","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601895734?lang=zh_cn&edition=full","pubTime":"2026-01-06 18:19","pubTimestamp":1767694786,"startTime":"0","endTime":"0","summary":"智通财经APP讯，毕得医药 发布公告，因股东自身流动性需求，股东欣曦管理、兰旦管理及其一致行动人吴波先生计划根据市场情况拟于本减持计划披露之日起15个交易日后的3个月内通过集中竞价、大宗交易方式减持其所持有的公司股份。减持价格将按照减持实际实施时的市场价格确定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"1132256178","title":"毕得医药股东拟减持不超过总股本3%股份，减持期1月28日至4月27日","url":"https://stock-news.laohu8.com/highlight/detail?id=1132256178","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132256178?lang=zh_cn&edition=full","pubTime":"2026-01-06 18:12","pubTimestamp":1767694351,"startTime":"0","endTime":"0","summary":"毕得医药（股票代码：688073）近日披露重要股东减持计划。根据公告，公司部分股东拟通过集中竞价或大宗交易方式，在2024年1月28日至4月27日期间，合计减持不超过公司总股本3%的股份。\n此次减持计划涉及多名股东，减持原因包括自身资金需求等因素。若按当前股价估算，此次减持规模可能达到数亿元。市场人士指出，大规模减持可能对二级市场股价形成短期压力，但长期仍需关注公司基本面变化。\n值得注意的是，本次减持计划实施期间恰逢上市公司年报披露窗口期。根据相关规定，股东在敏感期内减持需严格遵守减持规则，避免触碰监管红线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0216","688073"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770669557454,"stockEarnings":[{"period":"1week","weight":0.0528},{"period":"1month","weight":-0.1152},{"period":"3month","weight":-0.1512},{"period":"6month","weight":0.0409},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.0051}],"compareEarnings":[{"period":"1week","weight":0.0267},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0301},{"period":"6month","weight":0.1194},{"period":"1year","weight":0.248},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海毕得医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"3493人(较上一季度减少7.64%)","perCapita":"12377股","listingDate":"2022-10-11","address":"上海市杨浦区翔殷路128号11号楼A座101室","registeredCapital":"9088万元","survey":" 上海毕得医药科技股份有限公司的主营业务是为新药研发机构提供专业、高效的药物分子砌块及科学试剂产品及服务。公司的主要产品是分子砌块杂环化合物、分子砌块苯环化合物、分子砌块脂肪族类化合物、催化剂和配体、活性小分子化合物。","listedPrice":88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"毕得医药(688073)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供毕得医药(688073)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"毕得医药,688073,毕得医药股票,毕得医药股票老虎,毕得医药股票老虎国际,毕得医药行情,毕得医药股票行情,毕得医药股价,毕得医药股市,毕得医药股票价格,毕得医药股票交易,毕得医药股票购买,毕得医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"毕得医药(688073)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供毕得医药(688073)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}